Regeneron Buys Partner Decibel Therapeutics for Up to US$213 M

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 9 (Table of Contents)

Published: 7 Sep-2023

DOI: 10.3833/pdr.v2023.i9.2802     ISSN: 1756-7874

Section: Mergers & Acquisitions



Expanding its presence in gene therapies, Regeneron has agreed to acquire Decibel Therapeutics for a total equity value of approximately US$109 M at closing, which could rise to approximately US$213 M if contingent value right (CVR) milestones are achieved...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details